Mark Bittner
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, Nuclear Receptors and Signaling, Enzyme function and inhibition, Melanoma and MAPK Pathways
Most-Cited Works
- → Kinetic analysis of secretion from permeabilized adrenal chromaffin cells reveals distinct components.(1992)209 cited
- → Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin(2011)200 cited
- → OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models(2006)80 cited
- → A temperature-sensitive step in exocytosis.(1992)78 cited
- → Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics(2013)26 cited
- → Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2(2011)22 cited
- → Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors(2012)20 cited
- → Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1(2013)20 cited
- → Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics(2013)17 cited
- → Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs)(2005)16 cited